Posted On: 12/03/2015 12:14:43 PM
Post# of 87
$IDRA recently that announced it has entered into an exclusive worldwide collaboration and license agreement with GSK to research, develop and commercialize selected molecules from Idera’s 3rd generation antisense platform for the treatment of selected targets in renal disease.
"Under the terms of the agreement, Idera is eligible to receive approximately $100 million in development and regulatory milestone payments, including a $2.5 million upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500 million."
http://ir.iderapharma.com/phoenix.zhtml?c=208...ID=2114634
"Under the terms of the agreement, Idera is eligible to receive approximately $100 million in development and regulatory milestone payments, including a $2.5 million upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500 million."
http://ir.iderapharma.com/phoenix.zhtml?c=208...ID=2114634
(0)
(0)
